

Bruce A Perkins

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5212505/bruce-a-perkins-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

183 papers	10,123 citations	49 h-index	98 g-index
196 ext. papers	11,824 ext. citations	8.3 avg, IF	6.18 L-index

#	Paper	IF	Citations
183	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes.. <i>Journal of Diabetes and Its Complications</i> , 2022 , 36, 108134	3.2	0
182	Orthostatic blood pressure changes and diabetes duration.. <i>Journal of Diabetes and Its Complications</i> , 2022 , 108169	3.2	1
181	Impact of government-funded insulin pump programs on insulin pump use in Canada: a cross-sectional study using the National Diabetes Repository. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	1
180	Discoveries from the study of longstanding type 1 diabetes. <i>Diabetologia</i> , 2021 , 64, 1189-1200	10.3	4
179	Vitamin D Levels and the Risk of Posttransplant Diabetes Mellitus After Kidney Transplantation. <i>Progress in Transplantation</i> , 2021 , 31, 133-141	1.1	0
178	Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107880	3.2	2
177	Glycaemic control in transition-aged versus early adults with type 1 diabetes and the effect of a government-funded insulin pump programme. <i>Diabetic Medicine</i> , 2021 , 38, e14618	3.5	0
176	Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. <i>Science</i> , 2021 , 373, 522-527	33.3	9
175	Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study. <i>Diabetes Care</i> , 2021 , 44, 2107-2114	14.6	11
174	Afternoon aerobic and resistance exercise have limited impact on 24-h CGM outcomes in adults with type 1 diabetes: A secondary analysis. <i>Diabetes Research and Clinical Practice</i> , 2021 , 177, 108874	7.4	0
173	Baseline omega-3 level is associated with nerve regeneration following 12-months of omega-3 nutrition therapy in patients with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107798	3.2	7
172	Impact of a Gluten-Free Diet on Quality of Life and Health Perception in Patients With Type 1 Diabetes and Asymptomatic Celiac Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1984-e1992	5.6	3
171	Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1272-1281	6.7	8
170	Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107807	3.2	3
169	Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2466-2475	6.7	2
168	The Prevalence of Autoimmune Diseases in Longstanding Diabetes: Results from the Canadian Study of Longevity in Adults with Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 512-518.e1	2.1	1
167	Kidney Effects of Empagliflozin in People with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1715-1719	6.9	1

166	SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing. <i>Proteomics</i> , 2021 , 21, e2100160	4.8	2
165	Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 641-649.e4	2.1	1
164	Allopurinol adherence, persistence and patterns of use in individuals with diabetes and gout: A retrospective, population-based cohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1162-1169	5.3	1
163	Impact of government-funded insulin pump programs on insulin pump use in Canada: a cross-sectional study using the National Diabetes Repository. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9, e002371	4.5	1
162	Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. <i>Diabetes Care</i> , 2020 , 43, 1553-1556	14.6	8
161	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020 , 382, 2493-2503	59.2	100
160	Rethinking Neuropathy in Type 1 Diabetes: Had We Lost Sight of What Matters Most?. <i>Diabetes Care</i> , 2020 , 43, 695-697	14.6	3
159	Talking Points for Helping Your Type 1 Diabetes Patient Decide About Hybrid Closed Loop. <i>Canadian Journal of Diabetes</i> , 2020 , 44, 356-358	2.1	2
158	Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 427-433	6.7	2
157	High fractional excretion of glycation adducts is associated with subsequent early decline in renal function in type 1 diabetes. <i>Scientific Reports</i> , 2020 , 10, 12709	4.9	2
156	Analysis of Prevalence, Magnitude and Timing of the Dawn Phenomenon in Adults and Adolescents With Type 1 Diabetes: Descriptive Analysis of 2 Insulin Pump Trials. <i>Canadian Journal of Diabetes</i> , 2020 , 44, 229-235	2.1	1
155	Graves Disease After Chronic Hypothyroidism in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2020 , 44, 131-132	2.1	0
154	Rapid Corneal Nerve Fiber Loss: A Marker of Diabetic Neuropathy Onset and Progression. <i>Diabetes Care</i> , 2020 , 43, 1829-1835	14.6	22
153	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 547-549	3.2	1
152	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. <i>Diabetes</i> , 2019 , 68, 1649-1662	0.9	15
151	Estimating GFR by Serum Creatinine, Cystatin C, and β -Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Kidney International Reports</i> , 2019 , 4, 786-796	4.1	8
150	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1716-1723	14.6	5
149	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. <i>Renal Failure</i> , 2019 , 41, 427-433	2.9	3

148	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019 , 42, 1454-1463	14.6	28
147	AuthorsReply to: "The role of long-term effects of allopurinol on cardiovascular outcomes and all-cause mortality in diabetes". <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2181-2182	6.7	
146	Uric Acid Levels Correlate with Sensory Nerve Function in Healthy Subjects. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 337-341	1	4
145	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 883-890	14.6	37
144	Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus. <i>Diabetologia</i> , 2019 , 62, 1090-1093	10.3	13
143	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 786-796	7.4	7
142	Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1322-1329	6.7	11
141	Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	2
140	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 107397	3.2	5
139	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1388-1398	6.7	8
138	Sounding the alarm on rising diabetes-related amputations. <i>Cmaj</i> , 2019 , 191, E953-E954	3.5	1
137	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 107324	3.2	12
136	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 575-583	6.7	9
135	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 273-280	14.6	8
134	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. <i>Canadian Journal of Neurological Sciences</i> , 2018 , 45, 346-349	1	3
133	Sex differences in neuropathic pain intensity in diabetes. <i>Journal of the Neurological Sciences</i> , 2018 , 388, 103-106	3.2	18
132	Neuropathy. <i>Canadian Journal of Diabetes</i> , 2018 , 42 Suppl 1, S217-S221	2.1	16
131	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 831-839	14.6	11

130	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 424-428	3.2	2
129	High frequency of MGUS in DSP. <i>Muscle and Nerve</i> , 2018 , 57, 1018-1021	3.4	
128	Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. <i>Diabetologia</i> , 2018 , 61, 1856-1861	10.3	71
127	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. <i>JCI Insight</i> , 2018 , 3,	9.9	25
126	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>PLoS ONE</i> , 2018 , 13, e0196647	3.7	8
125	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. <i>Clinical Neurophysiology</i> , 2018 , 129, 122-126	4.3	7
124	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. <i>Diabetes Care</i> , 2018 , 41, 88-95	14.6	16
123	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018 , 41, 2560-2569	14.6	149
122	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 2570-2578	14.6	27
121	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 660-664	3.2	16
120	Peripheral nerve high-resolution ultrasound in diabetes. <i>Muscle and Nerve</i> , 2017 , 55, 171-178	3.4	45
119	Using in vivo corneal confocal microscopy to identify diabetic sensorimotor polyneuropathy risk profiles in patients with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017 , 5, e000251	4.5	12
118	Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. <i>Diabetes</i> , 2017 , 66, 1939-1949	0.9	20
117	Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. <i>Neurology</i> , 2017 , 88, 2294-2301	6.5	68
116	Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 501-512	18.1	253
115	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1318-1324	3.2	23
114	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2017 , 379, 94-98	3.2	8
113	Urinary adenosine excretion in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 313, F184-F191	4.3	29

112	Assessment of urinary microparticles in normotensive patients with type 1 diabetes. <i>Diabetologia</i> , 2017 , 60, 581-584	10.3	50
111	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. <i>Journal of the Neurological Sciences</i> , 2017 , 372, 223-227	3.2	10
110	The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. <i>PLoS ONE</i> , 2017 , 12, e0186910	3.7	15
109	Meta-analysis of artificial pancreas trials: methodological considerations - AuthorsReply. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 685-686	18.1	0
108	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017 , 5, e000461	4.5	5
107	Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?. <i>Canadian Journal of Diabetes</i> , 2017 , 41, 6-9	2.1	11
106	Agreement between automated and manual quantification of corneal nerve fiber length: Implications for diabetic neuropathy research. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1066-1073	3.2	22
105	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetologia</i> , 2017 , 60, 2529-2531	10.3	12
104	Disease activity in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2016 , 369, 204-209	3.2	9
103	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1969-1977	6.9	69
102	Frequent laboratory abnormalities in CIDP patients. <i>Muscle and Nerve</i> , 2016 , 53, 862-5	3.4	15
101	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. <i>Cardiovascular Diabetology</i> , 2016 , 15, 14	8.7	22
100	The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. <i>Diabetologia</i> , 2016 , 59, 1860-70	10.3	112
99	Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 716-22	3.2	19
98	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. <i>Diabetes Care</i> , 2016 , 39, e67-8	14.6	17
97	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. <i>PLoS ONE</i> , 2016 , 11, e0165731	3.7	26
96	Reference values for ultrasonography of peripheral nerves. <i>Muscle and Nerve</i> , 2016 , 53, 538-44	3.4	51
95	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016 , 18, 298-307	8.1	22

94	A rapid decline in corneal small fibers and occurrence of foot ulceration and Charcot foot. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 1437-1439	3.2	14
93	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. <i>Circulation</i> , 2016 , 134, 752-72	16.7	631
92	Uric acid as a biomarker and a therapeutic target in diabetes. <i>Canadian Journal of Diabetes</i> , 2015 , 39, 239-46	2.1	77
91	Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1136-44	6.9	29
90	Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 537-46	5.1	11
89	Choosing drugs for the treatment of diabetic neuropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1805-14	4	5
88	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 119-26	4.8	45
87	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , 2015 , 38, 793-800	14.6	82
86	Normative values for corneal nerve morphology assessed using corneal confocal microscopy: a multinational normative data set. <i>Diabetes Care</i> , 2015 , 38, 838-43	14.6	113
85	Evaluation of a clinical tool to test and adjust the programmed overnight basal profiles for insulin pump therapy: a pilot study. <i>Canadian Journal of Diabetes</i> , 2015 , 39, 364-72	2.1	4
84	In vivo corneal confocal microscopy and prediction of future-incident neuropathy in type 1 diabetes: a preliminary longitudinal analysis. <i>Canadian Journal of Diabetes</i> , 2015 , 39, 390-7	2.1	44
83	Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 308, F77-83	4.3	105
82	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. <i>PLoS ONE</i> , 2015 , 10, e0139689	3.7	6
81	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. <i>PLoS ONE</i> , 2015 , 10, e0142309	3.7	29
80	The Celiac Disease and Diabetes-Dietary Intervention and Evaluation Trial (CD-DIET) protocol: a randomised controlled study to evaluate treatment of asymptomatic coeliac disease in type 1 diabetes. <i>BMJ Open</i> , 2015 , 5, e008097	3	20
79	Diabetic Neuropathies. <i>Seminars in Neurology</i> , 2015 , 35, 424-30	3.2	14
78	Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a randomized controlled trial. <i>Canadian Journal of Diabetes</i> , 2015 , 39, 50-4	2.1	4
77	Resistance Exercise in Already-Active Diabetic Individuals (READI): study rationale, design and methods for a randomized controlled trial of resistance and aerobic exercise in type 1 diabetes. <i>Contemporary Clinical Trials</i> , 2015 , 41, 129-38	2.3	7

76	Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes. <i>Diabetes Care</i> , 2015 , 38, 671-5	14.6	101
75	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. <i>PLoS ONE</i> , 2015 , 10, e0139674	3.7	7
74	Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. <i>PLoS ONE</i> , 2015 , 10, e0141085	3.7	26
73	The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2014 , 13, 28	8.7	313
72	Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?. <i>Canadian Journal of Diabetes</i> , 2014 , 38, 356-63	2.1	32
71	Prospective association of 25(OH)D with metabolic syndrome. <i>Clinical Endocrinology</i> , 2014 , 80, 502-7	3.4	36
70	Reliability and validity of a point-of-care sural nerve conduction device for identification of diabetic neuropathy. <i>PLoS ONE</i> , 2014 , 9, e86515	3.7	51
69	The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study. <i>PLoS ONE</i> , 2014 , 9, e89344	3.7	26
68	Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. <i>Kidney International</i> , 2014 , 86, 1057-8	9.9	80
67	Response to comment on Breiner et al. Does the prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to type 1 diabetic patients? <i>Diabetes care</i> 2014;37:1418-1424. <i>Diabetes Care</i> , 2014 , 37, e242	14.6	1
66	Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. <i>Diabetes Care</i> , 2014 , 37, 1480-3	14.6	186
65	White blood cell subtypes, insulin resistance and β cell dysfunction in high-risk individuals--the PROMISE cohort. <i>Clinical Endocrinology</i> , 2014 , 81, 536-41	3.4	33
64	Does the prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to type 1 diabetic patients?. <i>Diabetes Care</i> , 2014 , 37, 1418-24	14.6	78
63	Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. <i>Diabetologia</i> , 2014 , 57, 2599-602	10.3	102
62	Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. <i>Circulation</i> , 2014 , 129, 587-97	16.7	834
61	Measurement of cooling detection thresholds for identification of diabetic sensorimotor polyneuropathy in type 1 diabetes. <i>PLoS ONE</i> , 2014 , 9, e106995	3.7	14
60	Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. <i>Current Diabetes Reports</i> , 2013 , 13, 550-9	5.6	120
59	Resistance exercise in type 1 diabetes. <i>Canadian Journal of Diabetes</i> , 2013 , 37, 420-6	2.1	31

58	Conduction slowing in diabetic sensorimotor polyneuropathy. <i>Diabetes Care</i> , 2013 , 36, 3684-90	14.6	43
57	Insulin pump therapy is associated with less post-exercise hyperglycemia than multiple daily injections: an observational study of physically active type 1 diabetes patients. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15, 84-8	8.1	52
56	The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 240-2	3.2	15
55	Resistance versus aerobic exercise: acute effects on glycemia in type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 537-42	14.6	133
54	Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. <i>Diabetes Care</i> , 2013 , 36, 3208-15	14.6	103
53	Comparison of diabetes patients with "demyelinating" diabetic sensorimotor polyneuropathy to those diagnosed with CIDP. <i>Brain and Behavior</i> , 2013 , 3, 656-63	3.4	20
52	Point accuracy of interstitial continuous glucose monitoring during exercise in type 1 diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15, 46-9	8.1	40
51	Structure-function relationship between corneal nerves and conventional small-fiber tests in type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 2748-55	14.6	72
50	Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. <i>PLoS ONE</i> , 2013 , 8, e58783	3.7	42
49	Renal hyperfiltration and systemic blood pressure in patients with uncomplicated type 1 diabetes mellitus. <i>PLoS ONE</i> , 2013 , 8, e68908	3.7	18
48	Performing Resistance Exercise Prior to Aerobic Exercise Results in Higher Growth Hormone Levels during Exercise in Physically Active Individuals with Well-Controlled Type 1 Diabetes. <i>FASEB Journal</i> , 2013 , 27, 712.29	0.9	
47	Sural-to-radial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy. <i>Muscle and Nerve</i> , 2012 , 45, 126-7	3.4	10
46	The clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines. <i>Clinical Investigation</i> , 2012 , 2, 483-489		1
45	Can ultrasound of the tibial nerve detect diabetic peripheral neuropathy? A cross-sectional study. <i>Diabetes Care</i> , 2012 , 35, 2575-9	14.6	72
44	Can improved glycemic control slow renal function decline at all stages of diabetic nephropathy?. <i>Seminars in Nephrology</i> , 2012 , 32, 423-31	4.8	8
43	Higher magnification lenses versus conventional lenses for evaluation of diabetic neuropathy by corneal in vivo confocal microscopy. <i>Diabetes Research and Clinical Practice</i> , 2012 , 97, e37-40	7.4	12
42	Point Accuracy of Interstitial Continuous Glucose Monitoring During Resistance and Aerobic Exercise in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2012 , 36, S14-S15	2.1	3
41	Diabetic neuropathy and axon reflex-mediated neurogenic vasodilatation in type 1 diabetes. <i>PLoS ONE</i> , 2012 , 7, e34807	3.7	17

40	Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. <i>PLoS ONE</i> , 2012 , 7, e35655	3.7	36
39	Ability of Cystatin C to detect changes in glomerular filtration rate after ACE inhibition in patients with uncomplicated type 1 diabetes. <i>Clinical and Experimental Hypertension</i> , 2012 , 34, 606-11	2.2	6
38	Detection of diabetic sensorimotor polyneuropathy by corneal confocal microscopy in type 1 diabetes: a concurrent validity study. <i>Diabetes Care</i> , 2012 , 35, 821-8	14.6	149
37	Heart rate variability and sensorimotor polyneuropathy in type 1 diabetes. <i>Diabetes Care</i> , 2012 , 35, 809-16	14.6	24
36	Effects of performing resistance exercise before versus after aerobic exercise on glycemia in type 1 diabetes. <i>Diabetes Care</i> , 2012 , 35, 669-75	14.6	114
35	How sensitive is the case definition for diabetic sensorimotor polyneuropathy to the use of different symptoms, signs, and nerve conduction parameters in type 1 diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2011 , 92, e16-9	7.4	6
34	Dorsal versus ventral monofilament testing of the great toe for the identification of diabetic sensorimotor polyneuropathy. <i>Diabetes Research and Clinical Practice</i> , 2011 , 93, e71-e73	7.4	3
33	Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 168-75	5.6	95
32	Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. <i>Diabetes Care</i> , 2011 , 34, 2403-5	14.6	86
31	Prospective associations of vitamin D with β -cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. <i>Diabetes</i> , 2011 , 60, 2947-53	0.9	103
30	In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. <i>Kidney International</i> , 2010 , 77, 57-64	9.9	188
29	Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. <i>Diabetes Care</i> , 2010 , 33, 1549-54	14.6	62
28	Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. <i>Diabetes Care</i> , 2010 , 33, 1379-81	14.6	240
27	Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. <i>New England Journal of Medicine</i> , 2010 , 363, 311-20	59.2	664
26	Exercise and glucose metabolism in persons with diabetes mellitus: perspectives on the role for continuous glucose monitoring. <i>Journal of Diabetes Science and Technology</i> , 2009 , 3, 914-23	4.1	81
25	Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes. <i>Diabetes Care</i> , 2009 , 32, 889-93	14.6	62
24	Diabetes complications and the renin-angiotensin system. <i>New England Journal of Medicine</i> , 2009 , 361, 83-5	59.2	18
23	Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 2065-74	12.7	123

22	The consequences of anxious temperament for disease detection, self-management behavior, and quality of life in Type 2 diabetes mellitus. <i>Journal of Psychosomatic Research</i> , 2009 , 67, 297-305	4.1	31
21	Early nephropathy in type 1 diabetes: the importance of early renal function decline. <i>Current Opinion in Nephrology and Hypertension</i> , 2009 , 18, 233-40	3.5	46
20	Multi-site testing with a point-of-care nerve conduction device can be used in an algorithm to diagnose diabetic sensorimotor polyneuropathy. <i>Diabetes Care</i> , 2008 , 31, 522-4	14.6	18
19	Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007 , 2, 461-9	6.9	42
18	Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 1353-61	12.7	280
17	Efficacy of continuous real-time blood glucose monitoring during and after prolonged high-intensity cycling exercise: spinning with a continuous glucose monitoring system. <i>Diabetes Technology and Therapeutics</i> , 2006 , 8, 627-35	8.1	70
16	Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy. <i>Diabetes Care</i> , 2006 , 29, 2023-7	14.6	44
15	Objective evidence for the reversibility of nerve injury in diabetic neuropathic cachexia. <i>Diabetes Care</i> , 2006 , 29, 473-4	14.6	7
14	Type 1 Diabetes and Vigorous Exercise: Applications of Exercise Physiology to Patient Management. <i>Canadian Journal of Diabetes</i> , 2006 , 30, 63-71	2.1	86
13	Type 1 Diabetes and Exercise: Using the Insulin Pump to Maximum Advantage. <i>Canadian Journal of Diabetes</i> , 2006 , 30, 72-79	2.1	44
12	Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 1404-12	12.7	270
11	Early nephropathy in type 1 diabetes: a new perspective on who will and who will not progress. <i>Current Diabetes Reports</i> , 2005 , 5, 455-63	5.6	42
10	Emerging therapies for diabetic neuropathy: a clinical overview. <i>Current Diabetes Reviews</i> , 2005 , 1, 271-80	1.7	9
9	Early vascular risk factor modification in type 1 diabetes. <i>New England Journal of Medicine</i> , 2005 , 352, 408-9	59.2	8
8	Cooling detection thresholds in the assessment of diabetic sensory polyneuropathy: comparison of CASE IV and Medoc instruments. <i>Diabetes Care</i> , 2004 , 27, 1674-9	14.6	40
7	Diabetic neuropathy: a review emphasizing diagnostic methods. <i>Clinical Neurophysiology</i> , 2003 , 114, 1167-75	14.7	118
6	Regression of microalbuminuria in type 1 diabetes. <i>New England Journal of Medicine</i> , 2003 , 348, 2285-93	59.2	596
5	Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy. <i>Muscle and Nerve</i> , 2002 , 25, 212-7	3.4	23

4	Diagnosis and management of diabetic neuropathy. <i>Current Diabetes Reports</i> , 2002 , 2, 495-500	5.6	26
3	Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. <i>Diabetes Care</i> , 2002 , 25, 2048-52	14.6	272
2	Carpal tunnel syndrome in patients with diabetic polyneuropathy. <i>Diabetes Care</i> , 2002 , 25, 565-9	14.6	194
1	Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. <i>Diabetes Research and Clinical Practice</i> , 2001 , 54, 115-28	7.4	108